Core Viewpoint - Gilead Sciences is acquiring Ouro Medicines for $2.2 billion, marking its entry into the T-cell engager (TCE) market and strengthening its partnership with Galapagos [1] Group 1: Acquisition Details - Gilead will pay $1.68 billion upfront and up to $500 million in milestone payments for Ouro's BCMA/CD3-targeting TCE, gamgertamig (OM336), which is in clinical development for immune-mediated orphan diseases [2] - The acquisition aligns with Gilead's strategy to diversify beyond HIV and complements the autoimmune initiatives of its subsidiary, Kite [3] Group 2: Partnership with Galapagos - Galapagos may participate in the acquisition by covering half of the upfront and milestone payments and costs related to registrational trials for gamgertamig, while gaining 20-23% of net sales outside of greater China if the drug reaches the market [4] - The acquisition could enhance Galapagos' pipeline strategy as it restructures following the closure of its cell therapy unit [6] Group 3: Galapagos' Future Plans - Galapagos plans to utilize its €3 billion ($3.5 billion) cash reserves to acquire late-stage assets in immunology and oncology, moving away from cell therapies [7] - Currently, Galapagos is developing GLPG3667, an oral TYK2 blocker for systemic lupus erythematosus (SLE) and dermatomyositis, which has shown mixed efficacy in mid-stage trials [8] Group 4: T-cell Engagers in the Industry - Historically, TCEs have been developed primarily for oncology, with notable approvals for drugs like Johnson & Johnson's Tecvayli and AbbVie & Genmab's Epkinly in multiple myeloma and B-cell lymphomas [9]

Core Viewpoint - US-based biotechnology company Rallybio has entered into a definitive agreement to acquire Candid Therapeutics through a merger transaction, with the combined entity to operate as Candid Therapeutics and list on Nasdaq under the "CDRX" ticker symbol [1] Group 1: Acquisition Details - The merger will provide Candid with over $505 million in gross proceeds from a concurrent private financing round, supported by institutional investors [2] - The transaction is expected to close by mid-2026, pending customary closing conditions, including shareholder approval and regulatory clearances [3] Group 2: Financial Projections - The combined company anticipates a pro-forma cash balance of approximately $700 million at closing, which is projected to fund operations through 2030 [4][2] - Existing equityholders of Rallybio will hold 3.65% of the new merged entity, while equityholders of Candid, including financing investors, are projected to own around 96.35% [4] Group 3: Strategic Focus - The capital raised will be utilized to advance Candid's T-cell engager (TCE) portfolio, including planned Phase II studies for cizutamig targeting B-cell maturation antigen (BCMA) in myasthenia gravis and interstitial lung disease [3] - Rallybio's CEO emphasized the transaction as a compelling opportunity for stockholders to engage in the future value creation of a well-capitalized, clinical-stage company with a diverse TCE drug candidate portfolio [5] Group 4: Market Position and Collaborations - Candid's clinical data in myasthenia gravis and its autoimmune pipeline, along with strong backing from leading healthcare investors, supports the transaction's merit [6] - In April 2024, Rallybio announced a collaboration with Johnson & Johnson to advance therapeutic solutions for fetal and neonatal alloimmune thrombocytopenia (FNAIT) [6]